User-agent: Googlebot Disallow: User-agent: googlebot-image Disallow: User-agent: googlebot-mobile Disallow: User-agent: MSNBot Disallow: User-agent: Slurp Disallow: User-agent: Teoma Disallow: User-agent: Gigabot Disallow: User-agent: Robozilla Disallow: User-agent: Nutch Disallow: User-agent: ia_archiver Disallow: User-agent: baiduspider Disallow: User-agent: naverbot Disallow: User-agent: yeti Disallow: User-agent: yahoo-mmcrawler Disallow: User-agent: psbot Disallow: User-agent: yahoo-blogs/v3.9 Disallow: User-agent: * Disallow: Disallow: /cgi-bin/ Disallow: /nokia-3310.php Disallow: /twitter.php Disallow: /angular-js-developer.php Disallow: /customer-relationship-management.php Disallow: /travel-portal-development.php Disallow: /point-of-sale.php Disallow: /youtube.php Disallow: /delvein/blog/business-cocktail-14/ Disallow: /vue-js-developer.php Disallow: /delvein/blog/pd-1-and-pd-l-1-inhibitors-competitive-landscape-pipeline-and-market-analysis-2016-a-delveinsight-report/report-store.php Disallow: /delvein/blog/2015/11/ Disallow: /delvein/blog/2018/01/ Disallow: /matrimonial-portal-development.php Disallow: /delvein/blog/category/anti-coagulants/ Disallow: /delvein/blog/2016/11/ Disallow: /delvein/blog/2014/12/ Disallow: /delvein/blog/2017/10/ Disallow: /delvein/blog/2017/06/ Disallow: /delvein/blog/2016/03/ Disallow: /delvein/blog/2016/01/ Disallow: /delvein/blog/2016/12/ Disallow: /delvein/blog/category/atrial-fibrillation/ Disallow: /delvein/blog/category/business-consultant/ Disallow: /delvein/blog/category/gene-therapy-products/ Disallow: /delvein/blog/category/infographics/ Disallow: /delvein/blog/category/new-therapeutic-target/ Disallow: /123 Disallow: /services.php Disallow: /delvein/blog/nmda-receptor-antagonist-emerging-therapies-in-cns/ Disallow: /404.php Disallow: /?/news/ Disallow: /cgi-sys/suspendedpage.cgi Disallow: /index.php?_route_=nj-online-casinos/ Disallow: /nokia-3310-giveaway-winner.php Disallow: /sitemap.html Sitemap: https://www.cyberworx.in/sitemap.xml